Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Condition: Neuroblastoma Interventions: Drug: Naxitamab monotherapy; Drug: GM-CSF; Drug: Irinotecan; Drug: Temozolomide; Drug: Naxitamab in combination therapy; Drug: GM-CSF with combination regimen; Drug: Sintilimab Sponsors: Sun Yat-sen University; Hainan General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials